<DOC>
	<DOCNO>NCT00082836</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab yttrium Y 90 ibritumomab tiuxetan , locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . PURPOSE : This clinical trial study well give yttrium Y 90 ibritumomab tiuxetan together rituximab work treat patient recurrent primary CNS lymphoma .</brief_summary>
	<brief_title>Rituximab Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Recurrent Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine absorb radiation dose CNS lesion administration indium In 111 ibritumomab tiuxetan ( image ) patient recurrent primary CNS lymphoma . Secondary - Determine safety therapeutic dose yttrium Y 90 ibritumomab tiuxetan patient . Tertiary - Determine radiographic response patient treated drug . OUTLINE : Patients receive rituximab IV day 1 . Within 4 hour rituximab administration , patient receive indium In 111 ibritumomab tiuxetan IV 10 minute . Patients undergo whole body image . Patients whose dosimetry indicate CNS lesion would receive sufficient radioimmunotherapy dose receive therapeutic dose yttrium Y 90 ibritumomab tiuxetan IV 20-30 minute day 7 . Patients follow monthly 3 month , every 3 month 2 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma ( NHL ) Recurrent disease Isolated CNS relapse systemic NHL allow Primary CNS lymphoma Measurable gadoliniumenhancing lesion MRI brain No impair bone marrow reserve No hypocellular bone marrow No mark reduction bone marrow precursor one cell line ( granulocytic , megakaryocytic , erythroid ) No pleural effusion No chronic lymphocytic leukemia No AIDSrelated lymphoma PATIENT CHARACTERISTICS : Age Adult Performance status Not specify Life expectancy Not specify Hematopoietic Platelet count &gt; 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Other HIV negative No serious nonmalignant disease would preclude study participation No infection No antimurine antibody reactivity* No human antimouse antibody Not pregnant Negative pregnancy test NOTE : *Results must available prior study entry patient receive prior murine antibody proteins , rituximab PRIOR CONCURRENT THERAPY : Biologic therapy See Radiotherapy No prior stem cell transplantation No prior myeloablative therapy autologous bone marrow transplantation peripheral blood stem cell rescue No prior fail stem cell collection More 2 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy No 1 prior chemotherapy regimen Endocrine therapy Not specify Radiotherapy No prior radioimmunotherapy No prior wholebrain radiotherapy No prior external beam radiotherapy ( involved field regional ) &gt; 25 % active bone marrow Surgery More 4 week since prior major surgery except diagnostic surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>